• Boehringer Ingelheim GmbH, of Ingelheim, Germany, reported findings at the Asia Pacific Stroke Conference in Tokyo, confirming that, in Asian populations, Pradaxa (dabigatran etexilate) offered considerable benefits for the management of patients with atrial fibrillation.